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Abstract
Background: To evaluate the long-term results of chemoradiotherapy (CRT) for stage II-III thoracic esophageal
cancer mainly by comparing results of three protocols retrospectively.
Methods: Between 2000 and 2012, 298 patients with stage II-III thoracic esophageal cancer underwent CRT.
Patients in Group A received two cycles of cisplatin (CDDP) at 70 mg/m2 (day 1 and 29) and 5-fluorouracil (5-FU) at
700 mg/m2/24 h (day 1–4 and 29–32) with radiotherapy (RT) of 60 Gy without a break. Patients in Group B received
two cycles of CDDP at 40 mg/m2 (day 1, 8, 36 and 43) and 5-FU at 400 mg/m2/24 h (day 1–5, 8–12, 36–40 and
43–47) with RT of 60 Gy with a 2-week break. Patients in Group C received two cycles of nedaplatin at 70 mg/m2
(day 1 and 29) and 5-FU at 500 mg/m2/24 h (day 1–4 and 29–32) with RT of 60–70 Gy without a break. Differences
in prognostic factors between the groups were analyzed by univariate and multivariate analyses.
Results: The 5-year overall survival rates for patients in Group A, Group B and Group C were 52.4, 45.2 and 37.2 %,
respectively. The 5-year overall survival rates for patients in Stage II, Stage III (non-T4) and Stage III (T4) were 64.0,
40.1 and 22.5 %, respectively. The 5-year overall survival rates for patients who received 1 cycle and 2 cycles of
concomitant chemotherapy were 27.9 and 46.0 %, respectively. In univariate analysis, stage, performance status and
number of concomitant chemotherapy cycles were significant prognostic factors (p < 0.001, p = 0.008 and p < 0.001,
respectively). In multivariate analysis, stage, protocol and number of concomitant chemotherapy cycles were
significant factors (p < 0.001, p = 0.043 and p < 0.001, respectively).
Conclusions: The protocol used in Group A may be an effective protocol of CRT for esophageal cancer. It may be
important to complete the scheduled concomitant chemotherapy with the appropriate intensity of CRT.
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Background
Chemoradiotherapy (CRT) for thoracic esophageal can-
cer has better local control and overall survival than
does radiotherapy (RT) alone and is one of the curative
treatments for thoracic esophageal cancer [1]. Some
studies have shown that CRT for stage I esophageal can-
cer had a favorable treatment outcome [2, 3]. Although
esophagectomy with neoadjuvant therapy has been the
first choice of treatment for stage II-III, Ariga et al. and
Hironaka et al. reported that treatment outcomes after
CRT among patients with resectable thoracic esophageal
squamous cell carcinoma were comparable to outcomes
after surgery [4, 5]. A cisplatin (CDDP)-based combin-
ation as a regimen of CRT for thoracic esophageal can-
cer has become the standard and was used in some
clinical trials [6–9]. However, the optimal schedule and
dose of chemotherapy have not been established. More-
over, because techniques for radiotherapy such as inten-
sity modulated radiation therapy have been improved,
the current outcome of CRT for thoracic esophageal
cancer is expected to be better than that in past trials.
We evaluated the long-term results of CRT for stage
II-III thoracic esophageal cancer after 2000 mainly by
comparing results of three protocols retrospectively. We




Between 2000 and 2012, 298 patients with stage II-III
(T1-4 N0-1 M0: Union for International Cancer Con-
trol 2002) thoracic esophageal cancer underwent de-
finitive CRT. This study was performed according to
the principles of the Declaration of Helsinki (2013).
At the time the patients gave their consent for CRT,
we did not obtain comprehensive consent including
future research study. Because of retrospective study,
it is difficult to reacquire agreement from the pa-
tients or their family. Therefore, information disclos-
ure is being done to give a chance of participation
refusal on home page after Tohoku University School
of Medicine Institutional Review Board approved this
retrospective study (2014-1-543).
Radiotherapy
Gross tumor volume was defined as the primary tumor
and nodal metastasis based on upper gastrointestinal en-
doscopy, barium swallow, computed tomography (CT)
scan and positron emission tomography (PET). If it was
difficult to discriminate the primary tumor on RT plan-
ning, the clips were placed on the proximal and distal
sides of the primary tumor. Initial clinical target volume
(CTV) was defined as the region from the supraclavicular
to celiac lymph nodes. Initial CTV was made small in con-
sideration of the patient’s general condition. Boost CTV
was defined as the primary tumor with a 20–30 mm cra-
niocaudal margin and an approximately 5 mm radial mar-
gin and nodal metastasis. Planning target volume was
defined as CTV plus a 5–15 mm margin. Basically, the ini-
tial CTV received 40 Gy at 2 Gy per day using parallel-
opposed anterior-posterior fields. The boost CTV received
20–30 Gy at 2 Gy per day using parallel-oblique fields to
avoid the spinal cord. In some cases, dose per fraction was
set to 1.8 Gy in consideration of the patient’s general con-
dition and the size of RT fields.
Protocols
All patients underwent one of the following three proto-
cols of CRT (Fig. 1). Adjuvant chemotherapy after CRT
was performed in some patients. Patients in Group A re-
ceived two cycles of chemotherapy (2-h infusion of
CDDP at 70 mg/m2 on day 1 and continuous infusion of
5-fluorouracil [5-FU] at 700 mg/m2 over a 24-h period
on day 1–4) with a 4-week intervals and RT dose of
60 Gy. This protocol has been performed since 2009. Pa-
tients in Group B received two cycles of chemotherapy
(2-h infusion of CDDP at 40 mg/m2 on day 1 and 8 and
continuous infusion of 5-FU at 400 mg/m2 over a 24-h
period on day 1–5 and 8–12) with a 4-week intervals
and RT dose of 60 Gy with a 2-week break after 30 Gy.
This protocol has been performed mainly since 2000.
Patients in Group C received two cycles of chemother-
apy (2-h infusion of nedaplatin [CDGP] at 70 mg/m2 on
day 1 and continuous infusion of 5-FU 500 mg/m2 over
a 24-h period on day 1–5) with a 4-week interval and
RT dose of 60–70 Gy. This protocol has been performed
mainly since 2000. The decisions to assign patients to
the three protocols was made by experienced clinicians.
Fig. 1 Three protocols of chemoradiotherapy for thoracic esophageal cancer in the present study. Abbreviations: CDDP, cisplatin; 5-FU, 5-fluorouracil;
RT, radiotherapy; CDGP, nedaplatin
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Endpoints and follow-up
The primary endpoint of the present study was the 5-
year overall survival rate. The secondary endpoints were
progression-free survival rate, completion rate of the
protocol, pattern of the first relapse and late toxicity.
Upper gastrointestinal endoscopy, CT and PET were
performed for evaluation of locoregional relapse and dis-
tant metastasis every 3–6 months. We described the first
treatment at the time of the first relapse.
Late toxicities were graded according to the Common
Terminology Criteria for Adverse Events version 4.0. An
adverse effect more than 90 days after CRT was defined
as a late toxicity.
Statistical analysis
The characteristics of patients in Group A, Group B and
Group C were compared by the 2 × 2 chi-square test for di-
chotomous variables or the Mann–Whitney test for con-
tinuous variables. Overall survival rate and progression-free
survival rate were estimated using the Kaplan-Meier
method. Differences between patient subgroups for prog-
nostic factors were analyzed using the log-rank test as uni-
variate analysis. Overall survival was measured from the
start of RT to the date of death or last follow-up.
Progression-free survival was measured from the start of
RT to the date of first relapse or death due to any cause. If
salvage esophagectomy was performed due to a residual le-
sion after CRT, we made the date of salvage esophagectomy
the date of relapse. Age (66 years or less vs more than
66 years), gender (male vs female), performance status (PS)
(0 vs 1 vs 2), primary site (Upper thoracic esophagus vs
Middle thoracic esophagus vs Lower thoracic esophagus),
stage (II vs III (non-T4) vs III (T4)), protocol (Group A vs
Group B vs Group C), RT dose (60 Gy or less vs more than
60 Gy), number of concomitant chemotherapy cycles
(1 cycle vs 2 cycles), and adjuvant chemotherapy (with vs
without) were included in the log-rank test. Multivariate
analysis was performed using the Cox proportional hazards
regression model. All tests were two-sided, and statistical
significance was set at the level of p < 0.05. Statistical ana-
lysis was performed using JMP® 10 (SAS Institute Inc., Cary,
NC, USA).
Results
The patients’ characteristics are shown in Table 1. All pa-
tients had histologically proven squamous cell carcinoma.
The numbers of patients in Group A, Group B and Group
C were 48, 159 and 91, respectively. There were significant
differences in age, PS, stage, RT dose, number of concomi-
tant chemotherapy cycles and adjuvant chemotherapy be-
tween the three groups (p < 0.001, p < 0.001, p = 0.015, p <
0.001, p = 0.019 and p < 0.001, respectively). The median
ages of the patients in Group A, Group B and Group C
were 67, 66 and 70 years, respectively. The number of
patients with PS0/ PS1/ PS2 were 22/24/2, 17/120/10 and
15/57/15, respectively. The numbers of patient with stage
II/ stage III (non-T4)/ stage III (T4) in Group A, Group B
and Group C were 17/13/18, 47/83/29 and 30/37/24,
respectively.
The completion rates of RT in Group A, Group B and
Group C were 100 % (48/48), 95.0 % (151/159) and
97.5 % (89/91), respectively. Total dose at the cessation
of RT was 20–64 Gy (median, 40 Gy), and a total dose
of 70 Gy was planned in the prescription for 2 patients.
The reasons for cessation of RT were brain infarct in 1
patient, myelosuppression in 2 patients, severe radiation
pneumonia (Grade 5) in 2 patients, severe esophageal
Table 1 Patients’ characteristics
Characteristic Number of patients
Age at radiotherapy
66 years or less 140










Upper thoracic esophagus 91
Middle thoracic esophagus 160










60 Gy or less 221
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stenosis in 1 patient, esophagobronchial fistula in 1 pa-
tient, infective thrombus in 1 patient, poor general con-
dition in 1 patient, and refusal of RT in 1 patient. The
completion rates of 2 cycles of chemotherapy in Group
A, Group B and Group C were 79.1 % (38/48), 91.1 %
(145/159) and 80.2 % (73/91), respectively. In 19 pa-
tients, the dose intensity of chemotherapy in the second
cycle was reduced due to myelosuppression and renal
dysfunction. Adjuvant chemotherapy after CRT was per-
formed in 67 patients. The number of cycles of adjuvant
chemotherapy was 1–8 (median, 2). The number of pa-
tients who received adjuvant chemotherapy in Group A,
Group B and Group C who received adjuvant chemo-
therapy were 14 (29.1 %), 45 (28.3 %) and 8 (8.8 %),
respectively.
The median follow-up period was 23.4 months (range,
1.8–150.2 months). A total of 155 patients died during
the follow-up period. The 3- and 5-year survival rates in
all patients were 51.5 % (95 % confidence interval [CI],
45.5–57.6) and 43.5 % (95 % CI, 37.4–50.0), respectively.
Five patients died of second malignancy at 8.5–
87.8 months after CRT, and 5 patients died of esopha-
geal hemorrhage at 2.5–11.8 months after CRT. Results
of the log-rank tests presented in Table 2 show the 5-
year overall survival rate for each prognostic factor. The
2-year overall survival rates for patients in Group A,
Group B and Group C were 74.5 % (95 % CI, 59.4–85.5),
61.1 % (95 % CI, 53.1–68.6) and 51.1 % (95 % CI, 40.4–
61.8), respectively. The 5-year overall survival rates for
patients in Group A, Group B and Group C were 52.4 %
(95 % CI, 35.0–69.3), 45.2 % (95 % CI, 37.0–53.6) and
37.2 % (95 % CI, 26.8–48.8), respectively (Fig. 2). How-
ever, there were no significant differences between the
three groups (p = 0.082). In univariate analysis, stage, PS
and number of concomitant chemotherapy cycles were
significant prognostic factors (p < 0.001, p = 0.008 and
p < 0.001, respectively). The 5-year overall survival
rates for patients in stage II, stage III (non-T4) and
stage III (T4) were 64.0 % (95 % CI, 52.5–74.2),
40.1 % (95 % CI, 31.0–49.9) and 22.5 % (95 % CI,
13.7–35.5), respectively (Fig. 3). The 5-year overall
survival rates for patients who received 1 cycle and
patients who received 2 cycles of concomitant chemo-
therapy were 27.9 % (95 % CI, 14.5–46.9) and 46.0 %
(95 % CI, 39.3–52.8), respectively (Fig. 4). The 5-year
overall survival rates for patients with PS0, PS1 and
PS2 were 48.7 % (95 % CI, 33.1–64.6), 44.3 % (95 % CI,
36.7–52.1) and 22.3 % (95 % CI, 9.5–44.1), respectively.
There were no significant differences for total dose
(p = 0.09) and adjuvant chemotherapy (p = 0.885). The
results of multivariate analysis are shown in Table 2. Stage,
protocols and number of concomitant chemotherapy cycles
were significant factors (p < 0.001, p = 0.043 and p < 0.001,
respectively). The hazard ratios (HRs) for patients in stage
III (non-T4) and stage III (T4) were 2.60 (95 % CI,
1.68–4.11) and 4.17 (95 % CI, 2.47–7.12), respectively.
The HRs for patients in Group B and Group C were
1.99 (95 % CI, 1.11–3.78) and 2.14 (95 % CI, 1.09–4.35),
respectively. The HR with 1 cycle of concomitant chemo-
therapy was 3.17 (95 % CI, 1.96–5.02). We investigated
overall survival rates for protocols in each stage just for
reference. The 5-year overall survival rates for patients in
Stage II in Group A, Group B and Group C were 77.9 %
(95 % CI, 41.3–94.6), 68.3 % (95 % CI, 53.2–80.3) and
48.4 % (95 % CI, 28.7–68.7), respectively. The 5-year over-
all survival rates for patients in Stage III (non-T4) in
Table 2 Results of univariate and multivariate analyses






Age at radiotherapy 0.393 0.162
66 years or less 47.2 (38.7–55.9)








Primary site 0.714 0.810
Upper thoracic esophagus 38.9 (24.4–55.7)
Middle thoracic esophagus 42.9 (34.4–51.9)
Lower thoracic esophagus 46.6 (35.7–57.8)
Stage <0.001 <0.001
II 64.0 (52.5–74.2)
III (non-T4) 40.1 (31.0–49.9)
III (T4) 22.5 (13.7–35.5)
Protocol 0.082 0.043
Group A 52.4 (35.0–69.3)
Group B 45.2 (37.0–53.6)
Group C 37.2 (26.8–48.8)
Radiotherapy dose 0.090 0.973
60 Gy or less 46.0 (28.1–51.2)
More than 60 Gy 39.1 (38.7–53.5)
Concomitant chemotherapy <0.001 <0.001
1 cycle 27.9 (14.5–46.9)
2 cycles 46.0 (39.3–52.8)
Adjuvant chemotherapy 0.885 0.306
With 45.1 (38.1–52.5)
Without 38.8 (26.8–52.3)
OS overall survival, CI confidence interval, UA univariate analysis, MA
multivariate analysis
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Group A, Group B and Group C were 53.9 % (95 % CI,
25.5–80.0), 42.0 % (95 % CI, 30.8–54.1) and 39.2 %
(95 % CI, 23.6–57.4), respectively. The 5-year overall
survival rates for patients in Stage III (T4) in Group A,
Group B and Group C were 25.3 % (95 % CI, 7.5–58.6),
19.1 % (95 % CI, 7.9–39.6) and 24.3 % (95 % CI, 11.0–45.4),
respectively.
The 3-year and 5-year progression-free survival rates
in all patients were 35.6 % (95%CI, 30.3–41.4) and
31.2 % (95%CI, 19.6–39.9), respectively. The 5-year
progression-free survival rates for patients in Group A,
Group B and Group C were 46.6 % (95 % CI, 32.3–61.6),
29.0 % (95 % CI, 22.3–36.7) and 28.7 % (95 % CI,
19.6–39.9) (p = 0.130), respectively. The 5-year progression-
free survival rates for patients in stage II, stage III (non-T4)
and stage III (T4) were 47.3 % (95 % CI, 36.7–58.1), 29.5 %
(95 % CI, 22.0–38.3) and 12.8 % (95 % CI, 6.2–24.7)
(p < 0.001), respectively. The 5-year progression-free
survival rates in patients with 1 cycle and 2 cycles of con-
comitant chemotherapy were 23.3 % (95 % CI, 12.6–39.1)
and 32.7 % (95 % CI, 26.9–39.2) (p = 0.003), respectively.
The 5-year progression-free survival rates for PS0,
PS1 and PS2 were 43.1 % (95 % CI, 29.0–58.4), 29.5 %
(95 % CI, 23.3–36.7) and 15.9 % (95 % CI, 5.6–37.3)
(p = 0.032), respectively.
The patterns of the first relapse are shown in Table 3.
One hundred seventy patients had relapse after CRT,
and 109 patients had local relapse as the first relapse.
Many of the first relapses occurred within one year after
CRT. Salvage esophagectomy was performed in 31 pa-
tients who had local relapse and in 15 patients who had
a residual local lesion. Salvage esophagectomy was per-
formed in 16 patients in Stage II, 24 patients in Stage III
(non-T4) and 6 patients in Stage III (T4) (Group A: 3
patients, Group B: 33 patients, Group C: 10 patients).
The intervals from CRT to salvage esophagectomy were
1.5–29.2 months (median, 5.3 months). Two patients
died of pneumonitis and gastric conduit necrosis after
salvage esophagectomy. Salvage endoscopic mucosal re-
section or endoscopic submucosal dissection was per-
formed in 12 patients who had local relapse. The
intervals from CRT to salvage endoscopic therapy were
1.8–128.5 months (median, 14 months). Chemotherapy
was performed in 55 patients as treatment for the first
relapse after CRT and in 13 patients as treatment for re-
lapse after salvage esophagectomy. Chemotherapy for
locoregional relapse, distant metastasis and locoregional
plus distant metastasis was performed in 34, 25 and 9 of
the 68 patients, respectively (CDDP or CDGP + 5-FU:
29, CDGP + Taxane: 23, Taxane: 16). RT or CRT was
Fig. 2 Overall survival rates for Group A, Group B and Group C
Fig. 3 Overall survival rates for patients in stage II, stage III (non-T4)
and stage III (T4)
Fig. 4 Overall survival rates for patients who received 1 cycle and
2 cycles of concomitant chemotherapy
Table 3 Pattern of first relapse
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performed in 30 patients (esophagus: 4, lymph nodes:
21, distant metastasis: 5).
Late toxicities are shown in Table 4. Two patients died
of radiation pneumonitis at 5.9 months and 10.9 months
after CRT. Although those patients received steroid pulse
therapy, acute exacerbation was induced after that. One
patient had grade 4 radiation pneumonitis. That patient
recovered after steroid pulse therapy and use of a respir-
ator. Two patients had grade 3 radiation pneumonitis.
One patient died of myocardial infarction at 114.8 months
after CRT, though it was not clear whether this was caused
by RT. Six patients had grade 3 cardiac disorders (heart
failure: 2, acute coronary syndrome: 2, conduction dis-
order: 2). Grade 3 pleural effusion and pericardial effusion
were detected in 2 and 4 patients, respectively. Grade 3
esophageal stenosis or fistula was detected in 5 patients.
Hypothyroidsm was detected in 6 patients and they were
given levothyroxine sodium hydrate.
Discussion
We discuss the results of the present study from the point
of view of esophageal squamous cell carcinoma because
all patients had histologically proven squamous cell car-
cinoma. The 3-year and 5-year survival rates after CRT for
patients with stage II-III thoracic esophageal cancer
including T4 in our institution were 51.5 % (95 % CI,
45.5–57.6) and 43.5 % (95 % CI, 37.4–50.0), respectively.
The treatment results in the present study were better
than those in previous studies, indicating that CRT for
stage II-III thoracic esophageal cancer has been improved.
Esophagectomy with neoadjuvant chemotherapy in Japan
and esophagectomy with neoadjuvant CRT in Western
countries have been the main treatments for stage II-III
esophageal cancer as previously mentioned [10–12]. How-
ever, treatment results of CRT for stage II-III may be com-
parable to those of esophagectomy as shown in studies by
Ariga et al. and Hironaka et al. [4, 5]. A meta-
analysis of randomized trials in which definitive
(chemo-) radiotherapy was compared with either surgery
alone or surgery+/−induction treatment showed that
overall survival rates after surgery and definitive CRT were
similar, though there was a trend for more cancer-related
deaths in the definitive CRT groups due to a higher risk of
loco-regional progression [13]. Therefore, CRT is a rea-
sonable treatment of thoracic esophageal cancer. However,
the results of CRT for T4 esophageal cancer in the present
study were poor, as shown in other studies [14, 15]. Those
results indicate the importance of early detection of
esophageal cancer.
Local relapse rates after CRT were about 30 % in some
studies [4, 7, 16]. In the present study, 109 of the 298
patients had local relapse. Salvage esophagectomy has
been the main curative treatment for local relapse after
CRT, and salvage esophagectomy was performed in 46
patients in the present study. The large number of pa-
tients who received salvage esophagectomy may be the
main reason for the better overall survival rate in the
present study than the overall survival rates in previous
studies. It is a fact that there were some patients with
long-term survival after salvage esophageactomy. How-
ever, patients who underwent salvage esophagectomy
after definitive high-dose CRT had high rates of morbid-
ity and mortality [17]. Therefore, in the future, we may
need to select patients having sensitivity to CRT for
esophageal cancer more carefully.
Although local relapse has been a problem of CRT for
esophageal cancer, increasing the complete response rate
is an essential requirement to improve the results of
CRT. Ishikura et al. reported that 3-year and 5-year
overall survival rates were 63 and 51 %, respectively, for
complete response patients, whereas 3-year and 5-year
overall survival rates were 6 and 2 %, respectively, for
non-complete response patients [18]. Therefore, it may
be important to increase the treatment intensity of CRT
to some extent. In the present study, the overall survival
and progression-free survival rates in patients receiving
two cycles of chemotherapy were better than those in
patients receiving one cycle of chemotherapy between
all of protocol groups, though we did not show those re-
sults. Therefore, it may be important to complete the
scheduled protocol of CRT with the minimum of effort
to reduce side effects. We compared the treatment re-
sults of three protocols in the present study. Since pa-
tients in Group B had a 2-week break after 30 Gy, the
completion rate of CRT in Group B was the highest in
the three groups. In contrast, the progression-free sur-
vival rate in Group B was lower than that in Group A.
This might have been caused by protraction of RT. Pro-
traction of RT has been shown to be detrimental in pa-
tients with head and neck cancer [19, 20]. Crehange et
al. also reported that local control rate of a protocol with
a 2-week break during CRT was worse than that of a
protocol without a break in patients with T3N0-1
esophageal cancer [21]. Therefore, we may need to avoid
Table 4 Late toxicities
Study Grade 2 Grade 3 Grade 4 Grade 5
Radiation pneumonitis 3 2 1 2
Pleural effusion 13 2 0 0
Pericardial effusion 32 4 0 0
Heart 6 6 0 1
Skin 0 0 0 0
Esophagus 7 5 0 0
Spinal cord 0 0 0 0
Hypothyroidism 6 0 0 0
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unconsidered protraction of RT for esophageal cancer.
CDGP used in Group C showed anti-tumor activity
similar to that of CDDP and had less renal and gastro-
intestinal toxicity [22]. However, the treatment results in
Group C were worse than those in Group A. One of
those reasons might be that the general conditions of pa-
tients in Group C were poorer and they were older than
those in Group A and Group B. Group A had the high-
est intensity of treatment in the three protocols and the
protocol in Group A might be an effective CRT protocol
for esophageal cancer, though the follow-up period was
short and the number of patients in this group was small.
Although a regimen consisting of CDDP + 5-FU and RT
has been the standard for thoracic esophageal cancer, a
variety of protocols of concomitant chemotherapy have
been used. In the PRODIGE5/ACCORD17, definitive
CRT with an FOLFOX treatment regimen (5-FU plus leu-
covorin and oxaliplatin) was compared with 5-FU and
CDDP in patients with esophageal cancer [23]. In the
Study of Chemoradiotherapy in OesoPhageal cancer with
Erbitux (SCOPE) 1 trial, outcome of definitive CRT with
or that without the addition of cetuximab to CDDP and
5-FU in patients with esophageal cancer were compared
[24]. However, an improvement in overall survival was not
achieved in either of the trials. Protocols that are superior
to CDDP and 5-FU are expected to be established in the
future.
Two cycles of adjuvant chemotherapy after concomi-
tant CRT were performed in many prospective studies
[4, 6–9]. Although adjuvant chemotherapy is often per-
formed in patients with more advanced esophageal can-
cer, adjuvant chemotherapy had no significant benefit
for overall survival rate or progression-free survival rate
in the present study. Additional investigation of the ef-
fects of adjuvant chemotherapy may be necessary.
With respect to total RT dose, Intergroup (INT) 0123
carried out a clinical trial to compare standard dose RT
(50.4 Gy) and high-dose RT (64.8 Gy) combined with
CDDP and 5-FU [6]. They reported that there was no
significant difference in median survival (13.0 vs
18.1 months) and 2-year survival (31 % vs. 40 %) be-
tween the high-dose and standard-dose groups. There-
fore, a total RT dose of 50.4 Gy has often been used in
CRT for esophageal cancer, though the total RT dose in
the present study was 60–70 Gy. However, the treatment
results may not be the same as those in previous study
because RT techniques have been improving. Treatment
results have in fact been different in some studies. Suh
et al. reported that high-dose radiotherapy of 60 Gy or
more with concurrent chemotherapy for stage II-III pa-
tients improved locoregional control and progression-
free survival [25]. On the other hand, Kato et al. re-
ported that the 1-year and 3-year overall survival rates
after CRT at a dose of 50.4 Gy for stage II-III patients
were 88.2 and 63.8 %, respectively, and that there were
no deaths related to salvage surgery [16]. For compari-
son, a total dose of more than 60 Gy did not improve
overall survival in the present study and might have no
advantage. INT0123 also reported that 11 treatment-
related deaths occurred in the high-dose group and only
two deaths occurred in the standard-dose group [6].
That is one of the reasons why a total RT dose of
50.4 Gy has often been used in CRT for esophageal can-
cer in the U.S. The rates of late toxicities of Grade 3 or
greater were 37 to 46 % in INT0123. The rate of late
toxicities was 7.7 % in the present study, though those
might have been underestimated because the study was
a retrospective study. The rates of late toxicities in other
recent studies on CRT with a total RT dose of 60 Gy
were similar to that in the present study [18, 26]. Based
on those results, the appropriate total RT doses for pa-
tients with esophageal cancer who will undergo salvage
esophagectomy and those who will not undergo salvage
esophagectomy may be 50.4 Gy and 60 Gy, respectively.
There are some limitations in the present study. First,
there were significant differences in some prognostic fac-
tors between Group A, Group B and Group C. There
was no defined criteria due to the retrospective analysis
in the present study. If general conditions were good in
less than 80 years patients without renal, cardiac and
liver dysfunction, cisplatin-based regimens such as
Group A and Group B tended to be performed. There-
fore, selection bias may have affected outcomes of CRT
in the present study. The patients in Group C were older
and the general condition of patients in Group C was
poorer than patients in Group A and Group B, as stated
above. Second, we did not evaluate overall survival rate
in view of smoking and alcohol consumption. Therefore,
treatment outcomes and rate of completion of CRT
might also have been affected by those factors because
the patients, especially those in Group C, might have
had some comorbidities caused by those factors. Third,
the median follow-up period in Group A was shorter
than those in Group B and Group C because the proto-
col for Group A has been performed since 2009. There-
fore, the evaluation of 5-year overall survival rates in the
three groups might be inappropriate. However, the 2-
year overall survival rate in Group A was better than
those in Group B and Group C, and the protocol used
in Group A may therefore be an effective CRT protocol
be one of for esophageal cancer.
Conclusions
CRT for stage II-III thoracic esophageal cancer is ef-
fective, and long-term survival can be expected. How-
ever, local relapse was observed in many patients. In
the future, we may need to select patients having sen-
sitivity to CRT for esophageal cancer more carefully.
Umezawa et al. BMC Cancer  (2015) 15:813 Page 7 of 8
The protocol used in Group A may be an effective
protocol for esophageal cancer. It may be important
to complete the scheduled concomitant chemotherapy
with the appropriate intensity of CRT. Additional in-
vestigation is needed to improve overall survival.
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